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Abstract 
 
There is a growing interest in the delivery of peptide drugs by non-intravenous 
routes. This study attempted to determine the feasibility of delivery of a peptide 
drug via the buccal route with an orally disintegrating tablet. To accomplish this 
we determined an acceptable proportion of ingredients to make a tablet that 
would meet the FDA guidelines for orally disintegrating tablets, be palatable to a 
potential patient, and deliver the drug to the patient. Our study showed a 3/2/1 
mixture of gelatin/glycine/sorbitol when combined with the active pharmaceutical 
delivered an acceptable orally disintegrating tablet formulation which passed the 
FDA disintegration test. The stability of the drug in this formulation was also 
tested over three months with <5% of the initial drug having degraded. In 
summary, we were able to formulate an orally disintegrating tablet for a peptide 
drug that passed the FDA criteria for disintegration and was stable over a three-
month time period. 
 
Background 
 
Peptide derived medications are potentially excellent candidates for 
therapeutic application and their role in the clinic is expanding rapidly. (1) 
However, the delivery of peptide medications has always been a problem. They 
are usually delivered via intravenous or intramuscular injections which are not 
convenient routes for outpatient or chronic medications. Peptides are not stable 
in the acidic environment of the stomach, and are susceptible to enzymatic 
degradation in the GI tract. (2) These limitations of conventional administration 
routes allow buccal delivery to be a desirable method of administration. 
 
Buccal delivery is being increasingly utilized to administer medications via 
orally disintegrating films (ODF) and orally disintegrating tablets (ODT). The 
buccal tissue is highly vascularized and absorption via this route avoids the GI 
tract and first pass metabolism. (3) Delivery via the buccal route helps to avoid 
the use of needles, which require special training, bring a risk of infection, and 
require the patient to overcome their fear of injecting themselves. Buccal delivery 
allows a patient to take a product several times a day in a manner similar to oral 
tablets or capsules. The disadvantages of buccal delivery via ODT include: the 
patient mistakenly swallowing the tablet before it dissolves in the oral cavity, 
formulating the drug to not leave behind an unpleasant residue or taste, and 
formulating the drug to overcome the highly-keratinized tissue in the buccal 
cavity. The FDA recommends: that an ODT should disintegrate within 30s, weigh 
less than 500 mg, an ODT should be pleasant to the patient, masking any 
bitterness of the active drug, and not leave an unpleasant residue after 
disintegration. (4) 
 
Formulations of an ODT vary based on the active pharmaceutical 
ingredient involved and the method of tablet formation. Freeze-drying is a proven 
method to generate a pleasant tablet without degrading the active ingredient. (5) 
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The matrix material is an important base for the ODT as it provides a porous 
structure in a low humidity environment while also quickly dissolving in water, 
gelatin is a preferred matrix. (6) Glycine was included based on its ability to 
increase the water solubility of the ODT and aid disintegration. (6) Sorbitol was 
utilized to also aid in disintegration and to allow for a more firm and pleasant 
appearing tablet. (7) The addition of the active pharmaceutical ingredient can 
have many impacts on the formulation of the ODT by altering the solubility, 
matrix structure, compressibility, and hygroscopicity. These factors were 
considered with the addition of DTI-100, but due to it being a hydrophilic peptide 
it aided in disintegration of the final ODT formulation without negatively affecting 
the tablet properties. 
 
The research presented here focuses on the formulation, manufacture, 
and stability of an ODT for delivery of a novel peptide drug, DTI-100, which was 
developed to help contract the muscles of the bladder and void the contents 
therein. This drug will help those without voluntary control of their bladder avoid 
life-threatening urinary tract infections and decrease the number of 
catheterizations needed to provide relief from a full bladder.  
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Figure 1 – Structure of DTI-100 
 
Materials and Methods 
 
Materials 
Gelatin, Glycine, Sorbitol, TFA, and acetonitrile were purchased from Fisher 
Scientific. DTI-100 was presented to us by Dignify Therapeutics, Durham, NC. 
 
Preparation of Orally Disintegrating Tablets 
ODTs were prepared using an experimental design approach where by more than 
one formulation parameter was adjusted in each experiment and the effect on 
tablet composition and disintegration time were measured to help select the best 
formulations. Stability under accelerated conditions and ability to incorporate DTI 
was then assessed to determine which formulation was suitable for our purpose. 
Based on the literature gelatin, glycine and sorbitol were selected as the main 
components for ODT preparation. Gelatin provides the matrix of the ODT, while 
glycine and sorbitol increase the water solubility of the ODT. All tablets were 
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prepared by combining all the components in a 10 mL glass vial before bringing 
the volume up to 2 mL with DI water. If required, some formulations were heated 
to 40 oC for 5 minutes to encourage all excipients to dissolve. When active drug 
was to be added, the solutions were allowed to cool to room temperature before 
the addition of the active drug. The final solutions were then added as 200 uL 
aliquots into blister pack molds and frozen at -80 oC prior to lyophilization under 
vacuum (200 Torr) using the step gradient method shown in Appendix 1 using a 
VirTis aDvantage wizard 2.0. Final lyophilized product was stored in a HDPE vial 
under nitrogen. 
 
Evaluation of Orally Disintegrating Tablets 
Following their preparation ODTs were visually inspected and their firmness 
graded from 1 (Soft) to 5 (Hard). The disintegration rate was assessed by placing 
the tablets in 2 mL of DI water and recording the time required for disintegration 
to occur. Disintegrated ODTs were analyzed via HPLC for content. 
 
HPLC Analysis Method 
Analysis was performed on a prominence HPLC (Shimadzu Corporation, Kyoto, 
Japan) equipped with a PDA detector. A reverse phase gradient separation was 
performed using a YMC Pack Pro C18 column 150 x 4.6 mm2 internal diameter 
with 3 µm particle size (YMC) at 45 oC and a flow rate of 1.0 mL/min. The mobile 
phases were composed of water with 0.1% trifluoroacetic acid (A) and 0.1% 
trifluoroacetic acid in acetonitrile (B). The mobile phase followed a gradient from 
95:5 to 90:10 for 5 min, then to 85:15 for 3 min, to 65:35 over 20 min after which 
the gradient remained at 65:35 for 2 min prior to re-equilibration of the system at 
95:5 for 5 min (Total 35 min). DTI-100 concentrations were analyzed at a 
wavelength of 220 nm across a range of 10 – 500 µg/mL.  
 
Stability of Orally Disintegrating Tablets 
The stability of DTI-100 ODTs were evaluated under accelerated stability 
conditions at both 25oC/65%RH and 40oC/75%RH. Before the study was initiated 
various storage container conditions were evaluated to determine the most 
appropriate material and desiccated HDPE bottles were selected. Tablets were 
placed in the HDPE bottles and at 0, 0.5, 1, and 3 months the DTI content and 
dissolution performance of the tablets was evaluated in triplicate.  
 
Results  
Optimization of ODT formulation 
Initially twelve formulations were prepared utilizing different ratios of excipients, 
and their properties were evaluated using DOE (Figures 1 & 2). Analysis of the 
data was performed in JMP to determine which components had the greatest effect 
on both the disintegration time and firmness of the tablets. The results show that 
gelatin had the greatest effect on both the firmness and disintegration time of the 
tablets. The glycine concentrations used had no effect on tablet performance and 
increasing sorbitol concentrations seem to play a minor role in firmness and 
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decreasing disintegration times. In general, as firmness of the tablet increases the 
disintegration time increases, though these are not directly correlated. 
From this point forward DTI was incorporated into the ODTs to ensure that its 
effects on the formulation were also assessed. Initially two concentrations of DTI 
were investigated: low dose (50 ug/tablet) and high dose (150 ug/tablet). These 
doses were selected based on preliminary in vivo efficacy data utilizing IV 
administration in a rat model. Based on the DOE analysis, a final component ratio 
was determined to be 3/2/1% gelatin/glycine/sorbitol. 
The DOE analysis was repeated to determine the effect of DTI-100 on the 
formulations. In general, DTI-100 has no effect on the firmness of the tablets and 
the disintegration times were increased slightly but still in the desired range of 
<30s. 
 
Based on the disintegration rate (<30s), final appearance (firm, white tablet with 
no deformities), and physical characteristics of the tablet, the 3/2/1% 
gelatin/glycine/sorbitol formulation was selected for further investigation. This 
formulation would be carried forward for stability and final product testing. 
 
Disintegration test 
Disintegration testing was performed to determine if the tablet would meet the 
FDA recommended criteria for an ODT. The final formulation of the ODT 
disintegrated in <30 seconds and did not leave a residue. The disintegration 
process required gentle agitation to help mimic the movement of saliva in the 
mouth. These were also conducted at room temperature and not at physiologic 
temperature.  
 
Stability of Orally Disintegrating Tablets 
The stability of the final ODT formulations was measured for 3 months under two 
different storage conditions of 25C/65% RH and 40C/75% RH. Three tablets per 
dosage strength from each storage condition was assessed at each time-point to 
determine the performance of the tablet via disintegration and test the content of 
the tablet to measure stability of the peptide in the formulation (Table 1). No 
decrease in performance was observed. The content of each tablet was 
measured by HPLC and there was no significant degradation observed over the 
first 90 days (Table 1). 
 
Conclusions 
This project was initiated to help develop an alternative delivery system for DTI-
100, a novel peptide designed to stimulate the bladder to help with voiding. ODT 
was chosen as the delivery system to allow the patient to control the delivery of 
the drug and to avoid degradation in the GI tract. The formulation of the ODT led 
to a 3/2/1% gelatin/glycine/sorbitol final product. These were found to be the 
optimal ratios of the components and allowed for easier manufacturing of the 
ODT. This formulation met the FDA guidelines for disintegration recommended 
for an ODT.  
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The stability of the formulation was verified over a three-month period using 
accelerated conditions. A storage condition needed for the tablets is bottling 
under nitrogen with calcium carbonate desiccant as the peptide is susceptible to 
hydrolysis if left exposed to room air for an extended period of time. This storage 
condition also helps to mimic a commercial manufacturing operation as ODTs 
are typically packaged in blister packs under a vacuum. 
 
However, early in vivo testing of the ODT showed that 20 times more of the drug 
was needed than initially calculated to achieve efficacious levels in the plasma of 
the rat model due to the highly-keratinized nature of the buccal cavity. This 
increase in the amount of drug contained in each ODT helped to decrease the 
disintegration time due to the hydrophilic nature of the peptide. This barrier to 
delivery is the focus of future work for this ODT formulation as overcoming the 
penetration issue while leaving the buccal mucosa intact would be an ideal 
method to help increase the bioavailability of the drug. 
 
In summary, this project developed the manufacturing process for the delivery of 
DTI-100 via the buccal route by an ODT formulation. The formulation was guided 
by DOE analysis and meets the criteria for disintegration set forth by the FDA. 
The formulation was also shown to be stable up to 90 days from manufacture 
under two storage conditions, and retained its performance and physical 
characteristics. 
 
Table 1 – Stability of DTI-100 under accelerated conditions 
 
Cond
ition 
(oC/
%RH
) 
Stren
gth 
(mg) 
Day 14 Day 28 Day 90 
Concentratio
n (mg) 
% Label 
Claim 
Concentratio
n (mg) 
% Label 
Claim 
Concentration 
(mg) 
% Label 
Claim 
25/6
0 1.5 
1 – 1.63 
2 – 1.58 
3 – 1.58 
 
1.59 
  
1 – 108.7 
2 – 105.3 
3 – 105.3 
106.4  2.0  
1 – 1.55 
2 – 1.55 
3 – 1.57 
1.56 
 
1 – 103.3 
2 – 103.3 
3 – 104.7 
103.8 
 
1 – 1.47 
2 – 1.43 
3 – 1.48 
1.46 
2 
1 – 97.8 
2 – 95.4 
3 – 98.5 
97.2 1.33 
25/6
0 5 
 1 – 5.09 
2 – 4.96 
3 – 5.05 
5.03 
 
1 – 101.8 
2 – 99.2 
3 – 101.0 
 100.7 
  
1 – 5.29 
2 – 5.19 
3 – 5.22 
5.23 
 
1 – 105.8 
2 – 103.8 
3 – 104.4 
104.7 
 
1 – 5.13 
2 – 5.10 
3 – 5.10 
5.11 
1 
1 – 102.6 
2 – 102.0 
3 – 102.1 
102.2 
0.26 
45/7
5 1.5 
 1 – 1.64 
2 – 1.49 
3 – 1.63 
1 – 109.1 
2 – 99.3 
3 – 108.7 
1 – 1.57 
2 – 1.56 
3 – 1.58 
1 – 104.6 
2 – 104.0 
3 – 105.3 
1 – 1.48 
2 – 1.45 
3 – 1.45 
1 – 98.6 
2 – 97.0 
3 – 96.5 
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1.59 
 
 105.7 
  
1.59 
 
104.6 
 
1.46 
1 
97.4 
90 
45/7
5 5 
1 – 4.89 
2 – 4.98 
3 – 5.00 
4.96 
  
1 – 97.8 
2 – 99.6 
3 – 100.0 
99.1 
  
1 – 4.75 
2 – 4.65 
3 – 5.08 
4.82 
 
1 – 95.0 
2 – 93.0 
3 – 101.6 
96.5 
 
1 – 4.90 
2 – 4.82 
3 – 5.04 
4.92 
09 
1 – 98.0 
2 – 96.4 
3 – 100.9 
98.4 1.88 
 
**For day 0 we used the content uniformity analysis as our starting 
concentrations. L- 1.6 mg and H- 5.4 mg. This was due to the quantity of tablets 
that could be manufactured in one day.
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Figure 2 – DOE Results for dependence of disintegration time on ODT 
components 
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Figure 3 – DOE Results depicting the dependence of ODT firmness on its 
components 
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APPENDIX I -Lyophilization Temperature Gradient 
 
Table 1 – Lyophilization Protocol 
Temperature 
(oC) 
Time (Min) 
-50 30 
-45 10 
-40 5 
-35 5 
-30 5 
-25 5 
-20 240 
-15 5 
-10 5 
-5 5 
0 5 
5 5 
10 5 
15 5 
20 90 
25 30 
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